MedTrace Logo

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

NCT07147751 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-08-29

No results posted yet for this study

Summary

PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.

Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.

Conditions

  • Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)

Sponsors & Collaborators

  • International Extranodal Lymphoma Study Group (IELSG)

    lead OTHER

Principal Investigators

  • Marco Paulli, MD · Unit of Pathology, IRCCS Policlinico San Matteo Foundation and Department of Molecular Medicine, University of Pavia (IT)

  • Marco Lucioni, MD · Unit of Pathology, IRCCS Policlinico San Matteo Foundation and Department of Molecular Medicine, University of Pavia (IT)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147751 on ClinicalTrials.gov